The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Thrombosis Research

• Publication date

  2012-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.thromres.2012.06.023PMID 22801256
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1.

  2012cited by this paper
• Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis.

  2012cited by this paper
• A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma.

  2012cited by this paper
• Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults

  2012cited by this paper
• A peptide mimicking the C‐terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type‐1

  2012cited by this paper
• Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo.

  2011cited by this paper
• Platelets Retain High Levels of Active Plasminogen Activator Inhibitor 1

  2011cited by this paper
• Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients.

  2011cited by this paper
• Biological significance of plasminogen activator inhibitor-1 expression in ovarian clear cell adenocarcinoma.

  2011cited by this paper
• Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus

  2011cited by this paper
• Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.

  2010cited by this paper
• A Novel Inhibitor of Plasminogen Activator Inhibitor-1 Provides Antithrombotic Benefits Devoid of Bleeding Effect in Nonhuman Primates

  2010cited by this paper
• Effect of the small molecule plasminogen activator inhibitor‐1 (PAI‐1) inhibitor, PAI‐749, in clinical models of fibrinolysis

  2010cited by this paper
• Characterization of a Novel Class of Polyphenolic Inhibitors of Plasminogen Activator Inhibitor-1*

  2010cited by this paper
• Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

  2010cited by this paper
• Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences.

  2010cited by this paper
• High quality structure of cleaved PAI-1-stab.

  2009cited by this paper
• New insights into the molecular mechanisms of the fibrinolytic system

  2009cited by this paper
• Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1)

  2009cited by this paper
• Antimetastatic Potential of PAI-1–Specific RNA Aptamers

  2009cited by this paper
• Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

  2009cited by this paper
• Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats.

  2009cited by this paper
• The effect of plasminogen activator inhibitor type 1 on apoptosis

  2008cited by this paper
• Plasminogen activator inhibitor type 1 deficiency

  2008cited by this paper
• S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood.

  2008cited by this paper
• The plasminogen activator inhibitor "paradox" in cancer.

  2008cited by this paper
• Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin.

  2008cited by this paper
• The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk.

  2008cited by this paper
• Dose-dependent thrombus resolution due to oral plasminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis

  2008cited by this paper
• Plasminogen activator inhibitor-1 and restenosis.

  2007cited by this paper
• Neutralization of Plasminogen Activator Inhibitor I (PAI-1) by the Synthetic Antagonist PAI-749 via a Dual Mechanism of Action

  2007cited by this paper
• Mechanism of Inactivation of Plasminogen Activator Inhibitor-1 by a Small Molecule Inhibitor*

  2007cited by this paper
• Vascular functions of the plasminogen activation system.

  2007cited by this paper
• Tiplaxtinin impairs nutritionally induced obesity in mice

  2006cited by this paper
• Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome

  2006cited by this paper
• Evidence for a Pre-latent Form of the Serpin Plasminogen Activator Inhibitor-1 with a Detached β-Strand 1C*

  2006cited by this paper
• An overview of the serpin superfamily

  2006cited by this paper
• PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences

  2006cited by this paper
• Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1

  2006cited by this paper
• Design and screening of antisense oligodeoxynucleotides against PAI-1 mRNA in endothelial cells in vitro

  2006cited by this paper
• A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide

  2005cited by this paper
• Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease

  2005cited by this paper
• Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice

  2005cited by this paper
• Antiplasmin: the forgotten serpin?

  2005cited by this paper
• Pleiotropic functions of plasminogen activator inhibitor‐1

  2005cited by this paper
• The catalytic triad of serine peptidases

  2005cited by this paper
• Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth

  2004cited by this paper
• Conservation of Critical Functional Domains in Murine Plasminogen Activator Inhibitor-1*

  2004cited by this paper
• Of Mice and Not Men: Differences between Mouse and Human Immunology

  2004cited by this paper
• The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors

  2004cited by this paper
• Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.

  2004cited by this paper
• Platelets synthesize large amounts of active plasminogen activator inhibitor 1.

  2004cited by this paper
• Inhibition of plasminogen activator inhibitor‐1: antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs

  2004cited by this paper
• Cloning and paratope analysis of an antibody fragment, a rational approach for the design of a PAI‐1 inhibitor

  2004cited by this paper
• Plasminogen activator inhibitor-1.

  2004cited by this paper
• Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.

  2004cited by this paper
• Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis

  2004cited by this paper
• Site-directed Targeting of Plasminogen Activator Inhibitor-1 as an Example for a Novel Approach in Rational Drug Design*

  2004cited by this paper
• Immobilization of the Distal Hinge in the Labile Serpin Plasminogen Activator Inhibitor 1

  2003cited by this paper
• Molecular Cancer BioMed Central

  2003cited by this paper
• A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.

  2003cited by this paper
• Biochemical importance of glycosylation of plasminogen activator inhibitor-1

  2003cited by this paper
• Mapping of a Conformational Epitope on Plasminogen Activator Inhibitor-1 by Random Mutagenesis

  2003cited by this paper
• Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.

  2003cited by this paper
• Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1

  2003cited by this paper
• Elucidation of a novel epitope of a substrate‐inducing monoclonal antibody against the serpin PAI‐1

  2003cited by this paper
• Importance of N-Terminal Residues in Plasminogen Activator Inhibitor 1 on its Antibody Induced Latency Transition

  2002cited by this paper
• Age-Dependent Spontaneous Coronary Arterial Thrombosis in Transgenic Mice That Express a Stable Form of Human Plasminogen Activator Inhibitor-1

  2002cited by this paper
• Do PAI-1 and vitronectin promote or inhibit neointima formation? The exact role of the fibrinolytic system in vascular remodeling remains uncertain.

  2002cited by this paper
• The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

  2002cited by this paper
• Characterization and Comparative Evaluation of a Novel PAI-1 Inhibitor

  2002cited by this paper
• A Novel Antithrombotic Role for High Molecular Weight Kininogen as Inhibitor of Plasminogen Activator Inhibitor-1 Function*

  2002cited by this paper
• The Fibrinolytic System and Obesity

  2002cited by this paper
• Disruption of the plasminogen activator inhibitor‐1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice

  2001cited by this paper
• The Distal Hinge of the Reactive Site Loop and Its Proximity

  2001cited by this paper
• Prospective Study of Fibrinolytic Factors and Incident Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study

  2001cited by this paper
• Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.

  2001cited by this paper
• Regulation of PAI-1 Concentration in Platelets by Systemic Administration of Antisense Oligonucleotides to Rats

  2001cited by this paper
• Vitronectin Functions as a Cofactor for Rapid Inhibition of Activated Protein C by Plasminogen Activator Inhibitor-1

  2001cited by this paper
• Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1.

  2001cited by this paper
• Identification of a Target Site in Plasminogen Activator Inhibitor-1 That Allows Neutralization of Its Inhibitory Properties Concomitant with an Allosteric Up-regulation of Its Antiadhesive Properties*

  2001cited by this paper
• Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.

  2001cited by this paper
• Acute Phase Protein α1-Acid Glycoprotein Interacts with Plasminogen Activator Inhibitor Type 1 and Stabilizes Its Inhibitory Activity*

  2001cited by this paper
• Structures of active and latent PAI-1: a possible stabilizing role for chloride ions.

  2000cited by this paper
• High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).

  2000cited by this paper
• Importance of the Hinge Region between α-Helix F and the Main Part of Serpins, Based upon Identification of the Epitope of Plasminogen Activator Inhibitor Type 1 Neutralizing Antibodies*

  2000cited by this paper
• PAI‐1 stability: the role of histidine residues

  2000cited by this paper
• Glycosylation dependent conformational transitions in plasminogen activator inhibitor-1: evidence for the presence of two active conformations

  2000cited by this paper
• Effect of Stabilizing versus Destabilizing Interactions on Plasminogen Activator Inhibitor-1

  2000cited by this paper
• Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.

  2000cited by this paper
• Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes.

  2000cited by this paper
• Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity.

  2000cited by this paper
• Structure of a serpin–protease complex shows inhibition by deformation

  2000cited by this paper
• Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.

  2000cited by this paper
• The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.

  1999cited by this paper
• Matrix Metalloproteinase System Deficiencies and Matrix Degradation

  1999cited by this paper
• The plasminogen activator system: biology and regulation

  1999cited by this paper
• Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.

  1998cited by this paper
• Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant

  1998cited by this paper
• Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.

  1998cited by this paper

• Integrated multi-omics and single-cell analysis identify SERPINE1 as a key mediator of the inflammatory tumor microenvironment in PDAC

  2026cites this paper
• Coagulation Gene Polymorphisms in Patients with Pediatric-Onset Non-Cirrhotic Portal Vein Thrombosis

  2026cites this paper
• PAI-1 Inhibition in experimental venous thrombosis.

  2026cites this paper
• The Role of p53‐Mediated Cellular Senescence in Idiopathic Pulmonary Fibrosis

  2025cites this paper
• Mechanistic insights into the PAI-1 inhibitor PAItrap3: enhancing lipid metabolism in adipose tissue of diabetic db/db mice

  2025cites this paper
• Possible contribution of the STAT3 signaling pathway to disseminated intravascular coagulation (DIC) in mice with cecal ligation and puncture-induced sepsis.

  2025cites this paper
• Identification of PANoptosis related biomarkers to predict hepatic ischemia‒reperfusion injury after liver transplantation

  2025cites this paper
• Indications of the SERPINE 1 variant rs1799768’s role in anti-VEGF therapy resistance in neovascular age-related macular degeneration

  2025cites this paper
• Aqueous humor cytokine profile in insufficient responder to aflibercept for neovascular age-related macular degeneration

  2025cites this paper
• PAI-1: A Key Signal at the Crossroads of Stem Cell Differentiation and Senescence

  2025cites this paper
• A Contemporary Review of Plasminogen Activator Inhibitor Type 1: Structure, Function, Genetic Architecture, and Intracellular/Extracellular Roles

  2025cites this paper
• M2 Macrophage-Derived Small Extracellular Vesicles Alleviate IVDD by Inhibiting Nucleus Pulposus Cell Fibrosis through the Akt/FOXO1/PAI-1 Axis

  2025cites this paper
• Accelerated aging and altered subclinical response to ozone exposure in young, healthy adults.

  2024cites this paper
• Chemical Adjustment of Fibrinolysis

  2024cites this paper
• A rapid crosslinking injectable polygalacturonic acid barrier modified with zwitterion bottlebrush for preventing postoperative adhesion

  2024cites this paper
• Propolis in the management of cardiovascular disease.

  2024cites this paper
• Matricellular proteins: Potential biomarkers in head and neck cancer

  2024cites this paper
• Increased galanin-galanin receptor 1 signaling, inflammation, and insulin resistance are associated with affective symptoms and chronic fatigue syndrome due to long COVID

  2024cites this paper
• Diagnostic indicators and lifestyle interventions of metabolic-associated fatty liver disease

  2024cites this paper
• Current insights and future directions of LncRNA Morrbid in disease pathogenesis

  2024cites this paper
• The effects of resistance training on cardiovascular factors and anti-inflammation in diabetic rats

  2024cites this paper
• Paclitaxel and Vinblastine Increase Plasminogen Activator Inhibitor-1 Production in Human Breast Cancer MCF-7 Cells but Not MDA-MB-231 Cells.

  2024cites this paper
• Immune Cells and Infectious Diseases in Pre-eclampsia Susceptibility.

  2024cites this paper
• PRKD3 promotes proliferation of liver cancer cells: a downstream proteomics profiling study.

  2024cites this paper
• Supplementation with Ashitaba (Angelica keiskei) Yellow Stem Exudate Prevents Aging-Induced Thrombotic Tendencies and Systemic Inflammation Without Affecting Body Weight Gain in Mice

  2023cites this paper
• Anti-PAI-1 Monoclonal Antibody Inhibits the Metastasis and Growth of Esophageal Squamous Cell Carcinoma

  2023cites this paper
• Identification of Genomic Loci Regulating Platelet Plasminogen Activator Inhibitor-1 in Mice.

  2023cites this paper
• miR-181a plays the tumor-suppressor role in chronic myeloid leukemia CD34 + cells partially via SERPINE1

  2023cites this paper
• Involvement of plasminogen activator inhibitor-1 in p300/p53-mediated age-related atrial fibrosis

  2023cites this paper
• Transcriptomics reveal a molecular signature in the progression of nonalcoholic steatohepatitis and identifies PAI‑1 and MMP‑9 as biomarkers in in vivo and in vitro studies

  2023cites this paper
• Body Mass Index and Waist Circumference as Determinants of Hemostatic Factors in Participants of a Population-Based Study

  2023cites this paper
• Functional, pathogenic, and pharmacological roles of protein folding intermediates

  2023cites this paper
• Hypofibrinolytic phenotype in Tsumura Suzuki Obese Diabetes (TSOD) mice unrelated to hyperglycemia.

  2023cites this paper
• Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation

  2023cites this paper
• Plasmin and plasminogen prevent sepsis severity by reducing neutrophil extracellular traps and systemic inflammation

  2023cites this paper
• A triple fusion tissue-type plasminogen activator (TriF-ΔtPA) enhanced thrombolysis in carotid embolism-induced stroke model.

  2023cites this paper
• Resistin Contribution to Cardiovascular Risk in Chronic Kidney Disease Male Patients

  2023cites this paper
• Laboratory evaluation of a new integrative assay to phenotype plasma fibrinolytic system

  2022cites this paper
• Features of plasminogen activator inhibitor-1 synthesis by local fat depots of different localization in cardiovascular diseases

  2022cites this paper
• PAI-1: A Major Player in the Vascular Dysfunction in Obstructive Sleep Apnea?

  2022cites this paper
• Angelica keiskei (Ashitaba) has potential as an antithrombotic health food

  2022cites this paper
• TM5614, an Inhibitor of Plasminogen Activator Inhibitor-1, Exerts an Antitumor Effect on Chronic Myeloid Leukemia.

  2022cites this paper
• Porphyromonas gingivalis Gingipains-Mediated Degradation of Plasminogen Activator Inhibitor-1 Leads to Delayed Wound Healing Responses in Human Endothelial Cells

  2021cites this paper
• Physiologie et exploration de la fibrinolyse

  2021cites this paper
• Serpins in Hemostasis as Therapeutic Targets for Bleeding or Thrombotic Disorders

  2021cites this paper
• The Central Role of Fibrinolytic Response in COVID-19—A Hematologist’s Perspective

  2021cites this paper
• The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis

  2021cites this paper
• PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target

  2021cites this paper
• The Role of Histone Protein Acetylation in Regulating Endothelial Function

  2021cites this paper
• PAI-1 expression in intratumoral inflammatory infiltrate contributes to lymph node metastasis in oral cancer: A cross-sectional study

  2021cites this paper
• SERPINA11 Inhibits Metastasis in Hepatocellular Carcinoma by Suppressing MEK/ERK Signaling Pathway

  2021cites this paper
• Urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma.

  2021cites this paper
• Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A

  2021cites this paper
• Hyperfibrinolysis

  2021cites this paper
• Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells

  2020cites this paper
• Preparasi sel mamalia CHO-DG44 dan isolasi plasmid dari bakteri Eschericia coli DH5-alfa sebagai tahap dalam produksi protein terapeutik erythropoetin sebagai obat anemia

  2020cites this paper
• Peptides based on the reactive center loop of Manduca sexta serpin-3 block its protease inhibitory function

  2020cites this paper
• Development of nanomedicines for inflammation disorders : evaluation of pharmacological efficacy on preclinical models

  2019cites this paper
• Identification of a PAI‐1‐binding site within an intrinsically disordered region of vitronectin

  2019cites this paper
• Plasminogen Activator Inhibitor Type 1 in Blood at Onset of Chemotherapy Unfavorably Affects Survival in Primary Ovarian Cancer.

  2019cites this paper
• Systemic oscillator-driven and nutrient-responsive hormonal regulation of daily expression rhythms for gluconeogenic enzyme genes in the mouse liver

  2019cites this paper
• Effects of Fermented Rice Vinegar Kurozu and Its Sediment on Inflammation-Induced Plasminogen Activator Inhibitor 1 (PAI-1) Increase

  2018influential citation
• Mast cell-derived plasminogen activator inhibitor type 1 promotes airway inflammation and remodeling in a murine model of asthma.

  2018cites this paper
• Combined treatment with benzo[a]pyrene and 1&agr;,25‐dihydroxyvitamin D3 induces expression of plasminogen activator inhibitor 1 in monocyte/macrophage‐derived cells

  2018cites this paper
• Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.

  2018cites this paper
• Biomarkers of Inflammation, Thrombogenesis, and Collagen Turnover in Patients With Atrial Fibrillation

  2018cites this paper
• Regulation of plasminogen activation on cell surfaces and fibrin

  2018cites this paper
• Trauma-Induced Coagulopathy: an Investigation of Fibrinolysis and the Effect of Tranexamic Acid

  2018cites this paper
• Circadian rhythm and sleep-wake systems share the dynamic extracellular synaptic milieu

  2018cites this paper
• Plasma levels of plasminogen activator inhibitor‐1 and bleeding phenotype in patients with von Willebrand disease

  2017cites this paper
• Platelets and Fibrinolysis

  2017cites this paper
• Conception de vecteurs polymères pour l’imagerie moléculaire et le traitement ciblé de la thrombose

  2017cites this paper
• Nanoplumbers: biomaterials to fight cardiovascular diseases

  2017cites this paper
• Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk

  2017cites this paper
• Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness.

  2017cites this paper
• Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study

  2017cites this paper
• Diagnosis and Treatment of Hyperfibrinolysis in Trauma (A European Perspective)

  2017cites this paper
• Relationship between plasma plasminogen activator inhibitor-1 and hypertension in American Indians: findings from the Strong Heart Study

  2017cites this paper
• Plasminogen Activator Inhibitor-1 is Regulated Through Dietary Fat Intake and Heritability: Studies in Twins

  2017cites this paper
• The SIRT1 inhibitor EX-527 suppresses mTOR activation and alleviates acute lung injury in mice with endotoxiemia

  2017cites this paper
• Seawater Immersion Aggravates Burn Injury Causing Severe Blood Coagulation Dysfunction

  2016cites this paper
• Plasminogen activator inhibitor‐1 as regulator of tumor‐initiating cell properties in head and neck cancers

  2016cites this paper
• The Roles of the High and Low Molecular Weight Isoforms of Fibroblast Growth Factor 2 in Ischemia-Induced Revascularization

  2016cites this paper
• Mast Cell-Derived PAI-1 Promotes Airway Inflammation and Remodeling in a Murine Model of Asthma*****

  2016cites this paper
• Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1

  2016cites this paper
• Generation and in vitro characterisation of inhibitory nanobodies towards plasminogen activator inhibitor 1

  2016cites this paper
• Relationship between preeclampsia and SERPINE1 (PAI-1-675 G4/G5) gene polymorphism. Systematic review. A metaanalysis

  2016cites this paper
• Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?

  2016cites this paper
• Adipose Tissue-Derived Plasminogen Activator Inhibitor-1 Function and Regulation.

  2016cites this paper
• Plasminogen activator inhibitor‐1 does not contribute to the pulmonary pathology induced by acute exposure to ozone

  2016influential citation
• Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1

  2016cites this paper
• uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy

  2016cites this paper
• The Epigenetic Reader BRD2 as a Specific Modulator of PAI-1 Expression in Lipopolysaccharide-Stimulated Mouse Primary Astrocytes

  2015cites this paper
• PAI-1 Inhibition - Another Therapeutic Option for Cardiovascular Protection.

  2015cites this paper
• Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE

  2015influential citation
• Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity

  2015cites this paper
• The role of serpins in tumor cell migration

  2015cites this paper
• Nanomedicine as a strategy to fight thrombotic diseases

  2015cites this paper
• ET-1 System Activity, Cardiovascular Disease Risk Factors and Pharmacologic Intervention

  2015cites this paper
• Fibrinolytic and procoagulant activities of Yersinia pestis and Salmonella enterica

  2015cites this paper